Frederic Luciano
Overview
Explore the profile of Frederic Luciano including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
7024
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sirera J, Sarlak S, Teisseire M, Carminati A, Nicolini V, Savy C, et al.
J Exp Clin Cancer Res
. 2024 Dec;
43(1):335.
PMID: 39736693
Background: Multiple Myeloma (MM) is the second most common hematological malignancy, characterized by the accumulation of monoclonal plasmocytes in the bone marrow. Despite advancements with proteasome inhibitors, immunomodulatory agents, and...
2.
Montemagno C, Jacquel A, Pandiani C, Rastoin O, Dawaliby R, Schmitt T, et al.
J Exp Clin Cancer Res
. 2024 Mar;
43(1):86.
PMID: 38504270
Background: In clear cell renal cell carcinoma (ccRCC), first-line treatment combines nivolumab (anti-PD-1) and ipilimumab (anti-CTLA4), yielding long-term remissions but with only a 40% success rate. Our study explored the...
3.
Hagege A, Saada-Bouzid E, Ambrosetti D, Rastoin O, Boyer J, He X, et al.
Cell Rep Med
. 2022 Sep;
3(9):100659.
PMID: 36130479
Local or metastatic relapse following surgery, radiotherapy, and cisplatin is the leading cause of death in patients with head and neck squamous cell carcinoma (HNSCC). Our study shows overexpression of...
4.
Montemagno C, Luciano F, Pages G
Methods Mol Biol
. 2022 Apr;
2475:1-23.
PMID: 35451746
Many cancers can be cured by combining surgery with healthy margins, radiation therapy and chemotherapies. However, when the pathology becomes metastatic, cancers can be incurable. The best situation involves "chronicization"...
5.
Hagege A, Ambrosetti D, Boyer J, Bozec A, Doyen J, Chamorey E, et al.
Theranostics
. 2021 Oct;
11(19):9571-9586.
PMID: 34646387
Head and neck squamous cell carcinoma (HNSCC) represent the 4 most aggressive cancer. 50% of patients relapse to the current treatments combining surgery, radiotherapy and cisplatin and die two years...
6.
Zerhouni M, Martin A, Furstoss N, Gutierrez V, Jaune E, Tekaya N, et al.
Cancer Res
. 2021 Jun;
81(14):3806-3821.
PMID: 34099492
Overcoming acquired drug resistance is a primary challenge in cancer treatment. Notably, more than 50% of patients with BRAF cutaneous metastatic melanoma (CMM) eventually develop resistance to BRAF inhibitors. Resistant...
7.
Roux B, Vaganay C, Vargas J, Alexe G, Benaksas C, Pardieu B, et al.
Sci Transl Med
. 2021 Apr;
13(587).
PMID: 33790022
The development and survival of cancer cells require adaptive mechanisms to stress. Such adaptations can confer intrinsic vulnerabilities, enabling the selective targeting of cancer cells. Through a pooled in vivo...
8.
Dubois A, Furstoss N, Calleja A, Zerhouni M, Cluzeau T, Savy C, et al.
Leukemia
. 2020 Jul;
34(9):2544.
PMID: 32665699
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
9.
Mondragon L, Mhaidly R, De Donatis G, Tosolini M, Dao P, Martin A, et al.
Cancer Cell
. 2019 Aug;
36(3):268-287.e10.
PMID: 31447347
GAPDH is emerging as a key player in T cell development and function. To investigate the role of GAPDH in T cells, we generated a transgenic mouse model overexpressing GAPDH...
10.
Dubois A, Furstoss N, Calleja A, Zerhouni M, Cluzeau T, Savy C, et al.
Leukemia
. 2019 Jan;
33(6):1501-1513.
PMID: 30607021
Chaperone-mediated autophagy (CMA) is a highly selective form of autophagy. During CMA, the HSC70 chaperone carries target proteins endowed with a KFERQ-like motif to the lysosomal receptor LAMP2A, which then...